The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term clinical outcomes and transcriptional analysis following partial and complete tumor SBRT plus pembrolizumab.
 
Sandeep Ramesh Bhave
No Relationships to Disclose
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical
 
Jeffrey Lemons
No Relationships to Disclose
 
Yuanyuan Zha
No Relationships to Disclose
 
Timothy C. Carll
No Relationships to Disclose
 
Thomas Krausz
No Relationships to Disclose
 
Hua Liang
No Relationships to Disclose
 
Linda A. Janisch
No Relationships to Disclose
 
Robyn D. Hseu
No Relationships to Disclose
 
Nikolai Khodarev
No Relationships to Disclose
 
Ralph R. Weichselbaum
Stock and Other Ownership Interests - Immune Cell Therapy
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - AstraZeneca; Merck KGaA
Research Funding - Regeneron; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Tvec
Travel, Accommodations, Expenses - AstraZeneca; Immune Cell Therapy
 
Sean Pitroda
No Relationships to Disclose
 
Steven J. Chmura
No Relationships to Disclose